Company & Sponsor Intelligence
Assistance Publique - Hôpitaux de Paris
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials4
Recruiting4
Completed0
Countries1
Therapeutic footprint
adhdunclassified
Indexed studies
NCT01870024Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus
epilepsy · FrancePHASE3
epilepsy · FrancePHASE3
NCT05284526EEG Recordings and Analysis in Parkinson's Patients: Towards Adaptive Deep Brain Stimulation by Machine Learning
parkinsons · FranceNA
parkinsons · FranceNA
NCT06858527Deficit Hyperactivity Disorder / Substance Use Disorder Comorbidity in Integrated Treatment
adhd · FranceNA
adhd · FranceNA
NCT07251673Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation
unclassified · FranceRECRUITING
unclassified · FranceRECRUITING
NCT04421846Study of Pathophysiology of Status Epilepticus and Dysimmune Encephalitis
unclassified · FranceNA
unclassified · FranceNA
NCT06351462Comparative Health Status and Quality of Life of Patients With Sickle Cell Disease (SCD) Who Underwent Matched-sibling Hematopoietic Stem Cell Transplantation Versus Non Transplanted SCD Case-control Patients
unclassified · NA
unclassified · NA
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →